Clinical Trial Update: A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B [Phase 1]

View source ↗

Summary

This is a completed Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of SAGE-718 oral solution in patients with Huntington's disease (Par…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SAGE-718

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Huntington Disease | Phase 1 | Status: COMPLETED